Trending...
- Passage of legislation to support creation of affordable housing, workforce training in Boston celebrated
- Massachusetts: Baker-Polito Administration Launches COVID-19 Vaccine CDC Pharmacy Partnership - Phase 1, Expands Vaccine Locations & Names Fenway Park as Mass Vaccination Site
- Boston: A message from Commissioner McCosh: Inauguration event accessibility
Study Finds Increase in Protein Nutritional Supplements Does Not Improve Mortality Rates for Hemodialysis Patients with Normal Nutritional Status
NASHVILLE, Tenn. - BostonChron -- Dialysis Clinic, Inc. (DCI) completed a three-year pragmatic trial of over 10,000 hemodialysis patients and concluded that adding an intensive oral protein nutritional supplement protocol does not improve mortality rates compared to patients receiving standard care.
"It is an accomplishment for the many patients who joined the study and for the clinical staff at DCI units to have undertaken a trial of this size and this scope and answered an important question. While it is disappointing that oral protein supplements, items like protein bars that you can buy at any store, did not lower mortality in hemodialysis patients with good nutritional status, it is important to say that this result does not tell us anything about giving protein supplements to people with low serum albumin. We do have observational data that suggest protein supplements have benefits in dialysis patients with low albumin," said Daniel Weiner, MD, of Tufts Medical Center in Boston and Medical Director of Clinical Research for DCI.
More on Boston Chron
The cluster randomized pragmatic study, named The HELPS-HD Trial, enrolled 10,457 patients from 105 DCI participating facilities. Patients were randomized to either the standard protocol group, whereby only those patients with an albumin level below 3.5 g/dL received supplement, or the intensive protocol group, where supplements were given to patients regardless of their albumin levels. The most common supplements used were protein bars, and all supplements had approximately 15g to 20g of protein. Mean follow-up was 21.2 months.
"We tried to keep this as real-world and pragmatic as possible," Weiner said.
At the conclusion of the study, there were 3,628 deaths, with 35.8% from the intensive group and 36.5% from the standard group. There was no significant difference in the death rate between the groups, even after adjusting for age, sex, race, and incident patient status.
"To be able to verbally consent over 10,000 patients in a randomized clinical trial is a testament to the dedication of the DCI staff to our patients and to our mission as a company. I am very proud to work for DCI and this incredible team in our quest to find the best possible care for our patients," said Karen Majchrzak, Director of Clinical Research at DCI.
More on Boston Chron
About DCI
Founded in 1971, Dialysis Clinic, Inc. (DCI) is the nation's largest non-profit dialysis provider with over 250 dialysis clinics in 30 states. Headquartered in Nashville, TN, DCI employs more than 5,000 people serving approximately 15,000 dialysis patients. DCI's services include in-center hemodialysis, in-center self-care hemodialysis, home hemodialysis, continuous ambulatory peritoneal dialysis (CAPD), continuous cycling peritoneal dialysis (CCPD) and Hospital Services (inpatient renal replacement therapy). For more information, visit www.dciinc.org.
"It is an accomplishment for the many patients who joined the study and for the clinical staff at DCI units to have undertaken a trial of this size and this scope and answered an important question. While it is disappointing that oral protein supplements, items like protein bars that you can buy at any store, did not lower mortality in hemodialysis patients with good nutritional status, it is important to say that this result does not tell us anything about giving protein supplements to people with low serum albumin. We do have observational data that suggest protein supplements have benefits in dialysis patients with low albumin," said Daniel Weiner, MD, of Tufts Medical Center in Boston and Medical Director of Clinical Research for DCI.
More on Boston Chron
- Boston: Update on the Ronan Park Well
- Avery Design Announces CXL™ 2.0 VIP
- Nova Biomedical FLEX2 Cell Culture Analyzer Adds Sample Retain Capability
- Kaizen Finance Launches Staking to Foster the Widespread Adoption of DeFi
- Ismail Sirdah Describes the Best Practices for Holding Corporate Events
The cluster randomized pragmatic study, named The HELPS-HD Trial, enrolled 10,457 patients from 105 DCI participating facilities. Patients were randomized to either the standard protocol group, whereby only those patients with an albumin level below 3.5 g/dL received supplement, or the intensive protocol group, where supplements were given to patients regardless of their albumin levels. The most common supplements used were protein bars, and all supplements had approximately 15g to 20g of protein. Mean follow-up was 21.2 months.
"We tried to keep this as real-world and pragmatic as possible," Weiner said.
At the conclusion of the study, there were 3,628 deaths, with 35.8% from the intensive group and 36.5% from the standard group. There was no significant difference in the death rate between the groups, even after adjusting for age, sex, race, and incident patient status.
"To be able to verbally consent over 10,000 patients in a randomized clinical trial is a testament to the dedication of the DCI staff to our patients and to our mission as a company. I am very proud to work for DCI and this incredible team in our quest to find the best possible care for our patients," said Karen Majchrzak, Director of Clinical Research at DCI.
More on Boston Chron
- MDAdvantage Appoints Pete Cammarano to Board of Directors
- CEO Coaching International Congratulates Client Orion Energy on Successful Capital Partnerships
- expEDIum Direct Pay®, seamless online payment added to iTech's expEDIum Medical Billing®
- Office Properties Income Trust Fourth Quarter 2020 Conference Call Scheduled for Friday, February 19th
- Haemonetics Welcomes New FDA Guidance on Viscoelastic Testing During COVID-19 Pandemic
About DCI
Founded in 1971, Dialysis Clinic, Inc. (DCI) is the nation's largest non-profit dialysis provider with over 250 dialysis clinics in 30 states. Headquartered in Nashville, TN, DCI employs more than 5,000 people serving approximately 15,000 dialysis patients. DCI's services include in-center hemodialysis, in-center self-care hemodialysis, home hemodialysis, continuous ambulatory peritoneal dialysis (CAPD), continuous cycling peritoneal dialysis (CCPD) and Hospital Services (inpatient renal replacement therapy). For more information, visit www.dciinc.org.
Source: Dialysis Clinic Inc. (DCI)
Filed Under: Health
0 Comments
Latest on Boston Chron
- Empirix Helps CEHE Confidently Migrate to Five9 Cloud-Based Contact Center Software USA - English USA - English
- Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area
- Manulife Investment Management announces new managing director of institutional distribution, southeast region
- Boston: Meet some of this year's Opportunity Fund grantees
- City Streaming TV, a Streaming Television Inc Network Launches, bringing Community and Faith Leaders into local TV's, At No Cost
- Perini Management Services, Inc. Announces Two Federal Contracts Collectively Valued at $66.9 Million
- "GLORY of HISTORY" Hip-Hop Music Video Looks At Voter's Choice
- BoatDealers.ca Surges with Record Traffic in 2020
- CoVerified Announces Partnership with Mirimus for Nationwide K-12 Pooled Saliva COVID-19 Testing Program
- Reify Health Announces Global Expansion of StudyTeam to Over 2,700 Clinical Research Sites
- 'Aesthetic Institute of Massachusetts' Announces Rebranding to 'Aesthetic Mentor'
- OCC Adopts Final Rule Requiring Large Banks to Provide Fair Access to Banking Services
- New GCI Study On Gynecologic Cancers in Brazil Finds Most Patients Present With Advanced Disease
- The Antenna Company Announces Venture Debt Financing Agreement with Brabant Development Agency (BOM)
- Haemonetics To Acquire Cardiva Medical, Inc. To Expand Hospital Portfolio
- Cohere Capital Completes Strategic Growth Investment in CCS, a Leading Digital Brand and E-Commerce Retailer
- Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
- Code18 Interactive Launches New Websites for Balmex and Balmex Adult
- LabMinds Successfully Receives Approval for Use in a GMP Certified Laboratory.
- The Atlas Group adds Corbin Raines to their list of professional property managers